Considering the narrow connection between coagulation, complement, and inflammation pathways, FXI inhibition could be considered in future trials as a potential approach for complement-mediated thromboses, such as antiphospholipid antibody syndrome (APS), and proinflammatory processes, such as cancer-associated thrombosis. Here, F11 is linked to autoimmune polyendocrinopathy.